Beruflich Dokumente
Kultur Dokumente
Contents
Introduction Risk factors Perioceutics Historical perspectives Host modulation
Host modulation options Classifications of agents Host modulation agents
Introduction
Periodontitis-- chronic infectious diseases.
Direct
Indirect
RISK FACTORS The severity of periodontal diseases, its rate of progression and
its response to therapy varies from patient to patient. The host must be susceptible and it is the patients factors that determine susceptibility of the disease risk
.
Genetics Hormonal Stress Smoking Systemic diseases
Nutritional deficiency Medications Faulty dentistry Poor oral hygiene History of periodontal disease
8
Host factor
Interference
Tissue destruction
Alter disease progression
PERIOCEUTICS
Use of pharmacological agents specifically developed to better mange periodontitis, is emerging to aid in the
Historical perspectives
As bacteria has been thought as main causative factor of
periodontitis, in the late 1970s and early 1980s, a few diverse research programs made out- standing progress that defined new opportunities for controlling periodontal disease by modulating the host response, instead of
11
The following were the major studies carried out: 1) Williams and colleagues (1985): using a beagle dog model of periodontal disease ,were able to demonstrate definitively that even in the presence of an excessive bacterial burden, it is possible to block disease progression significantly with a NonSteroidal Anti- Inflammatory Drug.
12
These investigators then examined the role of Prostaglandins in human periodontitis by blocking disease progression in subjects with periodontitis with the non steroidal anti-inflammatory drug Flurbiprofen. This was the first definitive proof that at least one specific host mechanism was in the critical path for periodontitis.
13
2. Golub and coworkers showed that (a) Collagenase enzymes were an active component of the destructive process in periodontitis (b) Tetracyclines and analogues without antibacterial activity were able to inhibit collagenases. 3. Multiple investigators were exploring the ability of bisphosphonates to prevent bone destruction in osteoporosis The scientific successes of these parallel developments ultimately led to the clinical application of host-modifying agents as a therapeutic approach to the treatment of periodontitis
14
HOST MODULATION
Host Modulation is a new term that has been incorporated into dentistry and has not been well defined.
From medical dictionary, Host the organism from which a parasite obtains its nourishment / in the transplantation of tissue, the individual who receives the graft. Modulation the alteration of function or status of something in response to a stimulus.
15
Anti-cytokine drugs
Antibody PMN Antigens Microbial challange LPS Other virulence factors Host immune Inflammatory Prostanoids response MMPs CT &bone metabolism Clinical signs of disease Cytokines
Mechanical treatment
17
Host modulation 1: Block Direct Effectors of Bone and Connective tissue Destruction Eg :Bisphosphonates ,MMP inhibitors Host modulation 2: Blocking host mechanisms that influnces clinical outcomes Eg:NSAIDS,Inhibitors of TNF alpha Host modulation 3: Host mechanisms that influences bacterial control Eg:agents that reduce levels of PGE2,IL-1,TNF etc
18
Modulation of arachidonic acid metabolites Eg:NSAIDS Modulation of MMPs Eg:TIMPs,Tetracyclines Modulation of bone remodelling Eg:Bisphosphonates Modulation of nitric oxide synthetase(NOS) Eg:Mercaptoethylglucanide
19
20
BISPHOSPHONATES:
Bisphosphonates : potent inhibitors of bone resorption by osteoclasts Have an effect on osteoblasts. Bisphosphonates are analogues of pyrophosphate a potent inhibitor of bone resorption.
Structurally similar to pyrophosphate( a normal product of human metabolism present in serum and urine) has calcium-chelating properties
21
HISTORY
Bisphosphonates :developed in the 19th century
Were first investigated in the 1960s for use in disorders of bone metabolism. The initial rationale for their use in humans :potential in preventing the dissolution of hydroxyapatite hence arresting bone loss.
CHEMISTRY
Pyrophosphate is produced by many anabolic processes. It is rapidly hydrolyzed to its two constituent phosphate groups. If the linking oxygen atom in the pyrophosphate molecule is replaced by a carbon atom, a bisphosphonate is formed. These analogues are completely resistant to hydrolysis and are chemically extremely stable. Like pyrophosphate, they bind to the hydroxyapatite crystals of bone and prevent their dissolution.
23
Classification
1. Based on the generation: First generation: with alkyl side chains E.g., etidronate Second-generation: amino-bisphosphonates with an amino-terminal group E.g., alendronate and pamidronate Third-generation: with cyclic side chains E.g., risedronate.
24
25
Association
Ronderus and colleagues (2000) reported that data from the NHANES III study suggested that osteoporosis is a risk factor for periodontitis. They observed more CAL in post menopausal women who did not receive estrogen therapy than in those who did.
Osteoporosis and periodontitis :- both are chronic diseases - prevalence in aging populations. -Involve osteoclastic bone resorption. Local production of cytokines appears to enhance osteoclastmediated bone resorption in estrogen-deficient patients. Peripheral blood monocytes from patients with osteoporosis secrete more interieukin-1 (IL-1).
26
Both disease processes involves mast cells, neutrophils, macrophages, lymphocytes, and plasma cells.
IL-6 is the most important cytokine in the recruitment of osteoclasts in abnormal osteoporotic bone remodeling.
in common.
27
Mecahnism of action
A. Direct action on osteoclasts:
Bisphosphonate mediate inhibition of osteoclasts
Induction of osteoclastic apoptosis through activation of the capasase pathway. Reduction of activity of osteoclasts
B. Indirect actions:
1- hydroxyethylidene-1, 1-bisphosphonate (HEBP) has osteostimulative properties both invitro and invivo HEBP mediated increases in matrix formation,, increased mineralized bone formation. HEBP treatment in vivo promotes osteoblastic differentiation in calvarial wounds, as well as a reversible stimulation of alveolar and calvarial bone width and reversible reductions in periodontal ligament space width.
29
30
Suppressies the interactions between the receptor activator of nuclear factor kappa B (RANK) and its ligand (RANKL) . Bisphosphonates down regulated activity levels of several MMPs including MMP-3, MMP-8 and MMP-13
31
Contraindication. Sensitivity to phosphate. Hypocalcaemia are present. For oral amino-bisphosphonates --> abnormalities of esophagus, which delay esophageal emptying such as stricture or achalasia, and inability to stand or sit upright for at least 30 minutes Drawbacks: Chronic administration over long periods to be effective. High cost Side effects: GI upset Esophageal ulcerations Chronic renal failure
32
Clinical parameters (PLI, GI, PPD) were not significantly affected by alendronate administration compared with placebo
34
35
Intraoral radiographs at baseline, 3 and 6 months. The mandibles processed for histolology at 6th month RESULTS:
Ouchi et al.(1998) studied the Effects of bisphosphonate administration on the progression of alveolar bone loss during ligature-induced experimental periodontitis in Beagle dogs with Systemic incadronate for 25 weeks. Incadronate administration prevented alveolar bone loss by reducing the increased alveolar bone turnover in dogs with experimental periodontitis
Alencar et al.(2002) studied the Effects of bisphosphonate administration on bone resorption during ligature-induced experimental periodontitis in Rats using Systemic clodronate for 11 days. Clodronate administration significantly reduced alveolar bone loss and inflammatory cell infiltrations compared with control animals
37
Mitsuta et al.(2002) studied the Effects of bisphosphonate administration on alveolar bone resorption during ligature-induced experimental periodontitis in Rats with Topical clodronate for 7 days. Topical clodronate significantly reduced bone mineral density changes and the number of osteoclasts per alveolar bone surface compared with control animals Tani-Ishii et al. (2003) studied the Effects of bisphosphonate administration on the progression of Porphyromonas gingivalis-induced experimental periodontitis in Rat using Systemic incadronate for 8 weeks. Systemic incadronate significantly inhibited alveolar bone resorption and PMN migration compared with control animals
38
Buduneli et al. (2004) studied the Effects of bisphosphonate administration on PGE2, PGF2a, and
39
40 with ChP
Placebo group: 40% of sites lost bone height Test group: 20% of sites lost bone height Test group: 1.31.3 mm difference in bone height and 0.52 0.85mm CAL gain compared with placebo
40
SRP
6 months
SRP
6 months
Significant difference (po0.001) in bone mineral density of maxilla and mandible . No significant difference in GI, PPD and CAL Ordinary dental treatment 45 years follow-up Improvements in clinical parameters (PPD and tooth mobility) and in alveolar bone density
41
Osteonecrosis
44
46
47
MMP inhibitors
Endogenous TIMPs
2- macroglobulins
Exogenous
48
Enodogenius agents
Both bind in a non-covalent fashion to member of MMP
family.
TIMPs :control MMP activities pericellularly, secreted by various cells found in serum and human saliva, present high concentration in healthy sites. 2- macroglobulin functions as a regulation of MMPs in
TIMPs:
Form high affinity, essentially irreversible non-covalent complex with the active form of MMPs. TIMP-1: - 30 KDa glycoprotein, synthesized and secreted by most connective tissue and macrophages. It binds to pro-gelatinase-B. TIMP2: - 21 KDa unglycolated proteins have 40% sequence identity with human TIMP 1. It binds to the proform of gelatinase A and involved in de activation.
50
TIMP -3- Isolated from chicken cells and cloned from human and mouse sources. It almost exclusively bonds to extracellular matrix. TIMP 4: - recently isolated. TIMP4 has been shown to interact with MMP2
51
B. Exogenous (Synthetic) Inhibitors: 1. Zn+ and Ca2+ chelating agents E.g. EDTA and 1, 10-phenananthrolin :are potent inhibitors of enzyme activity in vitro. Disadvantage toxic are not used as therapeutic agents 2) Synthetic peptides- as specific chelators: Phosphorus Containing Peptides E.g. Phosphonamidate, Phosphinate analog of tripeptides (Inhibits human skin fibroblast collagenase in vitro). -Substitues carbon atom with phosphorous atom in peptide substrate Sulphur based inhibitors e.g. Mercaptan derivatives: potent inhibitor of collagenase, gelatinase and stromelysins.
52
Bisphosphonates: Not a specifically designed MMP inhibitor, but inhibits MMP 1,3,8 & 13 in vitro by cation chelation. Phospholipase A2 inhobitors: Cranberry fraction
54
Tetracycline analogues
These are the only MMP inhibiters approved by FDA.
55
56
These ndings suggest that the tetracyclines(except for cmt-5) may bind to the secondary Zn2+ (and to a lesser extent,Ca2+) in collagenase, thus altering the conformation of the enzyme molecule and blocking its catalytic activity in the extracellular ma-trix. 57
pro-MMP
OXYDATIVE ACTIVATION
MMP
Indirect action:
.
1- antitrypsin
MMP
Serine proteinases
Tetracycline
59
60
61
62
CMT-3 - produced by removing the hydroxyl & methyl groups on carbon 6 & 4.
64
CMT 4 (7-Chloro 4 dedimethylamino tetracycline) CMT 7 (12a-deoxy-4-dedimethyl amino tetracycline) CMT 8 (4 dedimethyl doxycycline).
66
Experiment 2:
McNamara et al.1990 induced diabetes & exposed ODU (Osaka Dental University) rats to several Periodonto-pathogens (P.gingivalis,
Experiment - 3
Adult male Sprague-Dawley rats were monoinfected with P. gingivalis & it dramatically increased both gingival collagenase activity and alveolar bone loss compared with the uninfected controls. (Chang et al. ) Once again, the oral administration of doxycycline or CMT-1 sharply reduced collagenase activity and bone loss, even though the latter tetracycline compound is not an effective antimicrobial.
68
69
Mechanism of action
CMTs have been shown to downregulate expression of gelatinases, & thus to reduce the production of pro-enzyme (MMP-2 and MMP-9) (Golub et al., 1991, 1998). Also, CMTs may inhibit the activation of collagenases (MMP-1, MMP-8, and MMP-13), and Inhibit Stromelysins (MMP-3, MMP-10,and MMP-11) and
70
PMNs
Osteoblasts
Secretes
Procollagenase
Activated ROS e.g. HOCL by neutrophils
Collagenase
Inhibits 40 80%
CMT-1
71
Other mechanisms that have been proposed include: Inhibition of oxidative activation and increase in degradation of proMMP's, Inhibition of cytokine production, i.e., of TNF-alpha and IL-8, and Reduction of the expression of serine proteinase and trypsinogen-2. (Pruzanski et al., 1998; Kirkwood et al., 1999). Inhibition of non-collagenolytic proteases. Inhibit secretion of other collagenolytic enzymes like Lysosomal cathepsin.
72
NO is known to inhibit the synthesis of matrix constituents such as collagen and proteoglycans, as well as upregulate MMP expression. A series of CMTs exhibited the following efficacy as NOS inhibitors: CMT-3 and CMT-8 > CMT-1 and CMT-2 > CMT-5 (the latter exhibiting no inhibitory activity) (Trachtman et al., 1996; Amin et aL, 1997).
75
These data suggested that the relative potency of these compounds as inhibitors of NO production was positively correlated to their ability to function as MMP blockers.
Mechanism:
The suppression of NO synthesis by CMTs was found to be associated with reductions in iNOS expression apparently reflecting enhanced degradation of this enzyme's mRNA (Amin et aL, 1997).
The response of NOS to TCs provides an additional host-modulating nonantimicrobial therapeutic rationale for this family of drugs.
76
Bone resorption Inhibition: As examples of in vitro efficacy, TCs and CMTs were found to inhibit bone resorption in both organ and cell culture, regardless of whether the resorption was induced by parathyroid hormone (PTH), PGE2, or bacterial endotoxin (Golub et al, 1984; Gomes et al, 1984; Rifkin et al, 1994). CMT-1 and -3 and CMTs-6, -7, and -8 were effective inhibitors of bone resorption in culture (CMT-8 was the single most potent compound), whereas CMT-2, -4, and -5 were not.
77
78
Synergistic Actions:
Greenwald et al.' recently conducted a synergism study using CMT-1 + flurbiprofen, a standard nonsteroidal anti-inflammatory drug selected primarily because of its reported beneficial effect on bone loss in humans with adult periodontitis and the beagle dog model of periodontal disease.
79
CMTs potential advantages over conventional Tetracyclines: CMT-1 is absorbed after oral administration more rapidly and has a longer serum half life than tetracycline(observations in rats) Their long-term systemic administration does not result in gastrointestinal toxicity, No resistance.
80
National Cancer Institute has recently initiated preliminary studies, using CMT-3,
on humans with cancer.
More recent studies have demonstrated the therapeutic potential of TCs' antiMMP activity in in vivo and cell culture models of cancer invasion, metastasis, and angiogenesis ( Masumori et al, Lokeshwar et al, Seftor et al.)
81
84
85
Caton et al (2000) in 190 adult patients using 20 mg bid for 9 months + SRP showed significant improvements in CAL ( 2mm) PD and BOP when compared to placebo group receiving only SRP. Golub et al (2001) in 51 patients with active periodontitis based on pocket depth and increased collagenase at multiple exams using doxycycline 20 mg bid show no clinical attachment loss over 36 months.
86
Preshaw et al (2002) used doxy 20-mg bid for month and SRP in 208 chronic periodontitis subjects showed improvements in clinical
Novak et al (2002) in 20 subjects 45 yr. old patients with severe gen. periodontitis patients showing > 30% of sites with CAL 5 mm used doxycycline for 6 months. The result showed less CA loss and PD, GI and BOP when compared to placebo (not significant).
87
88
Contents
Introduction Risk factors Perioceutics Historical perspectives Host modulation Host modulation options Classifications of agents Host modulation agents Whom to treat with HMT? Conclusion References
89
90
phospholipase A2
Free arachidonic acid can then be metabolized via
92
AA metabolites mediators of tissue destruction in inflammatory diseases -including periodontal diseases. The majority of NSAIDs are weak organic acids inhibit selectively (COX-2) and non-selectively (COX-1) inhibit the synthesis of AA metabolites blocks the production
94
Goodson et al. (74) demonstrated that solutions containing prostaglandin E2 injected subcutaneously over the calvaria of adult rats stimulated rapid in vivo resorption of bone.
Nyman et al. : investigated the modulation of arachidonic acid metabolites with systemic indomethacin
98
(1979)
(1981)
99
100
101
102
months
months
103
104
105
106
Selective cyclooxygenase 2 inhibitors such as meloxicam, nimesulide, etodolac and celecoxib have potencies for cyclooxygenase 2 that are 10- to 1000-fold higher than for
cyclooxygenase 1.
Have fewer side effects - Lower gastric ulcer, lower bleeding tissue. NSAID:not approved by FDA
107
108
Serhan et al. (97) have recently described a novel series of oxygenated arachidonic acid derivatives called lipoxygenase interaction products or lipoxins which appear to function as endogenous anti-inflammatory mediators.
109
110
Inhibit polymorpho nuclear leukocyte adhesion. Stimulate vasodilatation Block some of the pro-inammatory effects of leukotrienes
111
Although neither of these agent classes has been therapeutically tested extensiveley in animals or humans with periodontal disease, they may logically present with reduced side effects or enhanced efficacy as compared with current NSAIDs.
112
LxA4 and its analogs, 1. Modulates IL-8 release at the gene transcriptional level 2. Suppress TNF- ,macrophage inflammatory peptide 2 and IL - 1 3. Enhance phagocytosis of apoptotic PMN by monocyte derived macrophages. .
113
114
115
Resolvins
Resolvins, a new family of biologically active products of omega-3 fatty acids, have the therapeutic potential to resolve periodontal inflammation and restore the gums to health. EPA : Resolvins of the E series (RvE1) DHA :Resolvins of the D series (RvD).
116
RvE1promotes resolution of inammation through direct limitation of PGE2 and cytokine secretion(solid red arrow). Indirect effects include blocking of osteoclast formation and secretion of antibacterial peptides by resident cells(open red arrows)
117
The local resolvin E1 (RvE1) application on experimental periodontitis in rabbits was experimented on. The results showed that compound has efficacy on preventing P. gingivalis induced periodontal disease and bone resorption.
In a rabbit model of human periodontal disease, local application of RvD1 in small amounts (4g/site) :complete resolution of inflammation and regeneration of bone.(H. HASTURK et al 2009)
118
119
120
Regulating Cytokines
Cytokines are defined as regulatory proteins controlling the survival, growth, differentiation and functions of cells. They are produced transiently at lower concentration and
121
These cytokines are present in diseased periodontal tissues and Gingival Crevicular Fluid (GCF) (Gemmell et al, 1997). Catabolic activities of cytokines controlled by endogenous inhibitors like IL-1 and TNF- receptor antagonists
123
When administered for therapeutic purposes, these antagonists can reduce inflammation. The use of cytokine receptor antagonists to inhibit
124
2001).
Cytokines implicated in suppression of the destructive
Both IL-4 and IL-10 can target macrophages and inhibit the release of IL-1, TNF-, reactive oxygen intermediates and NO. IL-4 induce programmed cell death (apoptosis) which reduced the number of inflammatory macrophages. It can also upregulate the production of IL-1 receptor antagonists (Wong et al, 1993).
126
Recently, recombinant human IL-11, which inhibits productions of TNF-alpha,IL-1 and NO, are also shown to reduce disease progression in a ligature-induced periodontitis canine model (Martuscelli et al, 2000).
127
The evidence that IL-4 is deficient in diseased periodontal tissues, and the finding of exogenous IL-4 administration in experimental arthritis which reduces inflammation, suggested that the use of this cytokine may provide a therapeutic benefit in the treatment of periodontal diseases
128
Currently, anticytokine therapy using anti-IL-1 or anti-tumor necrosis factor- monoclonal antibodies and soluble TNF- receptors have been approved for the treatment of rheumatoid arthritis, Crohns disease, juvenile arthritis and psoriatic arthritis with research continuing on periodontal disease.
129
Reduced the loss of connective tissue attachment and the loss of alveolar bone height Progression of periodontal disease can be retarded by antagonists to specific host mediators
Demonstrating s IL-1 and tumor necrosis factor inhibitors may provide a potential treatment modality to combat the disease process. (Delima et al.2001)
130
factor
131
Aldosterone inhibitor:has anti-TNF alpha activity Animal study didnt show positive result:may be due
to fast metabolism of drug, incomplete inhibition of TNF alpha
Pentoxifylline
Pentoxifylline (PTX), a methylxanthine derivative,
Thalidomide
Thalidomide was shown to inhibit TNF- production by enhancing the degradation of its messenger RNA without affecting the production of either IL-1 or IL-6 . Patient with erythema nodose of leprae, HIV, multiple myeloma or tuberculosis under TLD treatment displayed a reduction in clinical symptoms correlating with TNF- serum levels.
135
Anakinra (Kineret)
It is an interleukin-1 (IL-1) receptor antagonist. It competitively inhibits the binding of IL-1 to the Interleukin-1 type receptor.[Dashash Met al 2004] Anakinra blocks the biological activity of naturally occurring IL-1, including inflammation and cartilage degradation
136
Dosage is 100mg subcutaneously once daily Potential Side Effects injection site reactions infections and neutropenia malignancy immunogenecity
137
IL-4
Reduce the activity of AA pathway.
Reduces cytokine & enzyme production Stimulate apoptosis in-vitro
IL-10
Inhibits the antigen presenting capacity of macrophages Decreases proliferation and production of cytokines by activating T-cells. Suppress macrophages function & IL-12 production Inhibit macrophage derived IL-1, 6, 8
141
142
Increased in inflammation &tissues may be exposed to free radicals where there is abundance of Polymorphonuclear neutrophils and macrophages. HOCl act on the tissues through collagenase and gelatinase. They cause depolymerization of collagen, hyaluronan and proteoglycan which are normally neutralized by antioxidants
144
NOS1 & NOS3 are constitutively secreted from neuronal and endothelial cells respectively.
145
Inhibitor of iNOS
Merkaptoalkyguanides are inhibitors of iNOS : are found to decrease inflammation in animal models. They are found to, block iNOS
inhibit COX
Benedek et al (1998) demonstrated in a ligature-induced
151
Potassium channel blockers Therapies aimed at decreasing the expression of RANKL and pro-inflammatory cytokines by T-cells constitutes a
The potassium channels Kv1.3 and IKCa1, through the use of selective blockers, play important roles in T-cell-
cells(Valvare-2005)
153
Xylitol
Widely believed to possess anticaries properties.
Xylitol may have good clinical effect not only for caries
but also for periodontitis.
155
Tacrolimus
Since Tacrolimus, is an immunomodulatory drug used for the treatment of some cases of arthritis, it is hypothesized that it may modulate periodontal disease. In murine model of ligature-induced periodontal disease,
156
severity of periodontitis
157
(TIMP-1
158
oral hygiene.
160
But in individuals who exhibit severe generalized periodontitis with excessive immunoinflammatory response, host modulation with bacterial control seems to be an appropriate therapeutic strategy. Those include patients with diabetes, composite genotype, smoking, osteoporosis, stress, estrogen depletion, institutionalized geriatric patients etc.,
161
It becomes apparent that the use of systemic host modulatory therapy by the dentist may not only improve patients periodontal condition but also provide systemic benefits for other inflammatory disorders with related tissue destruction such as arthritis, CVD, dermatological conditions, diabetes, osteoporosis and so forth.
162
CONCLUSION
It is likely that management of disease or prevention of disease in individuals with signicantly in-creased risk for periodontitis will require either extreme bacterial control or combinations of bacterial control plus host modulators.
Though various agents are suggested only SDD & TETRACYCLINE are FDA approved. Further studies are needed to substantiate the use of other agents.
166
REFERENCES
Clinical infectious disease 1999;28 Clinical periodontology :Carranza Perio2000 ;14 Perio2000;24 Perio2000;48 CID 1999;28 JOP 2000,71 JOP2003 JCP 2004;31 JDR 2005;84 JDR 2006;85Oral health and preventive dentistry 2009;7 IJPRD 2008 JISP2009;13(2) Internet sources
167
168